Dermaxon received a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to demonstrate the effects of a preclinical candidate for the oral treatment of recalcitrant nodular acne.
Dermaxon, in collaboration with researchers at the University of Texas Medical Branch, is studying the neuroprotective effects of a CYP26 inhibitor under a grant sponsored by the Craig H. Neilsen Foundation.
DermaXon is proud to collaborate with researchers at the University of Texas Medical Branch on a project sponsored by the Department of Defense.